A.M.S. Mayer, Ph.D.
Professor of Pharmacology

Department of Pharmacology
Chicago College of Osteopathic Medicine
Midwestern University
555 31st Street
Downers Grove, IL 60515

 

 

Phone: (630) 515-6951
Fax: (630) 515-6295
E-mail: amayer@midwestern.edu

Home General Public Preclinical Pipeline Clinical Pipeline Seminars Meetings/Courses Links

MARINE PHARMACOLOGY:
THE CLINICAL PIPELINE

Compound Name Source Chemical Class Company Disease Area Status
Compounds targeting ion channels
Ziconotide (PrialtTM) Cone snail Peptide Elan Chronic pain FDA approved 2004, now marketed by Eisai in the EU
GTS-21 Nemertine worm Anabaseine-derivative NIMH (U. Colorado) Schizophrenia Phase II (Academic) completed
GTS-21 Nemertine worm Anabaseine-derivative Comentis Alzheimer/
ADHD
Phase II
Compounds targeting enzymes
Protein kinase inhibitors
Bryostatin-1 Bryozoan Polyketide NCI Cancer No current clinical trials. Potential interest in Alzheimers
Proteasome inhibitor
NPI-0052 Bacteria (Actinomycete) Beta-lactone-gamma-lactam Nereus Cancer Phase I
Microtubule-interacting agents
Dolastatin-10 Sea slug Peptide NCI/Knoll Cancer No details shown on NCI site after 2004
ILX-651 Sea slug Peptide Genzyme Cancer Preclinical as 4/2008, oral formulation being developed
E7389(eribulin) Sponge Halichondrin B analog Eisai Cancer Phase III for breast cancer USA & EU; Phase II (USA) NSCLC; Phase II (US/EU) prostate, Phase II (EU) sarcoma
NPI-2358 Fungi Diketopiperazine Nereus Cancer Phase II
TZT-1027(Soblidotin) aka YHI-501 Sea slug Peptide Aska Pharmaceuticals Cancer Phase I - III (possibly). Linked to monoclonals (Auristatin PE).
E-7974 Sponge Tripeptide Eisai Cancer Phase I
DNA and transcription interactive agents

Ecteinascidin-743-Trabectedin
(Yondelis®
)

Sea squirt Tetrahydroisoquinolone alkaloid PharmaMar/
Johnson & Johnson
Cancer Approved by EMEA Sept 2007
Phase III ovarian cancer completed file FDA/EMEA Fall 08
December 2008
Phase II prostate cancer ongoing
Phase II breast/lung cancer ongoing

PM00 104
(Zalypsis®)

Mollusc/Sponge Synthetic alkaloid based on Jorumycin PharmaMar Cancer Late Phase I development
VEGF interacting agent

Plitidepsin
(Aplidin®)

Sea squirt Cyclic depsipeptide PharmaMar Cancer Phase II multiple myeloma completed
Phase II in T-NHL ongoing
Combination studies ongoing
Lysosomotropic and ErbB interacting agent
Kahalalide F Sea slug/Algae Cyclic depsipeptide PharmaMar Cancer Phase II completed in solid tumors. Evaluated in severe psoriasis
PM02734 (Irvalec®) Sea slug Depsipeptide PharmaMar Cancer Phase I ongoing
Phase I/II in combination with Erlontinib in lung under implementation
Compounds with unknown mechanism of action
IPL-512602 Sponge Steroid Inflazyme/
Orexo pharmaceuticals
Inflammation/
Asthma
No further information available. Probably discontinued
Compounds targeting GPCRs
Pseudopterosin A-methyl ether (TMO) Soft Coral Diterpene glycoside Terosin Group Inc./Univ. of CA Wound Healing Phase II


Updated 3/30/2009 by A.M.S. Mayer, Ph.D.,  Pharmacology Department, CCOM, Midwestern University, Downers Grove, IL

60515, USA, Email: amayer@midwestern.edu  and  Keith B. Glaser, Ph.D.,  Global Pharmaceutical R&D, Cancer Research,   Abbott Laboratories,  Abbott Park, IL 60064-6121, USA. Email: Keith.Glaser@abbott.com.
Revised 3/25/2009 by D
avid J. Newman, Ph.D.,  Chief, Natural Products Branch, National Cancer Institute, Frederick, MD, 21701, USA. Email: newmand@mail.nih.gov.

Revised 3/23/2009 by Maria del Carmen Cuevas Marchante, Ph.D.,  PharmaMar S.A.,Avda. De los Reyes, 1, Pol. Ind. La Mina-Norte, 28770 Colmenar Viejo, Madrid, Spain. Email: ccuevas@pharmamar.com

Revised by 3/10/2009 by Barbara Potts, Ph.D., Nereus Pharmaceuticals, Inc.,San Diego, CA  92121, USA.. Email: bpotts@nereuspharm.com

Revised 3/18/2009 by Robert S. Jacobs, Ph.D., and Claudia Moya, Ph.D.,   University of California Santa Barbara, Santa Barbara, CA 93106-9610, USA. Email: rsjacobs@chem.ucsb.edu.

Revised 3/25/2009 by William Kem, Ph.D., University of Florida College of Medicine, Gainesville, FL 32610-0267. Email: wrkem@UFL.EDU

Revised 3/18/2009 by Alton Kremer, Eisai Medical Research Inc, Ridgefield Park, NJ 077660. Email: Alton_Kremer@eisai.com


Copyright © 2005-2009 Midwestern University. Last Rev. 6/22/2009. Direct questions or comments to Site Coordinator